OncologyMarket Opportunities, Strategies, and Forecasts, 2006 to 2012

Report # SH29821448 | 196 Pages | 97 Tables and Figures | 2006

Oncology Market Assessment

Check Out These Key Topics!
Oncology Market Shares, Forecasts, and Driving Forces
Nanotechnology Cancer Treatment Market Forecasts
Angiogenesis
Gold Nanoparticles And Lasers Cancer Surgery
SpectRx
Cancers
Lung
Breast
Colorectal
Ovarian
Prostate
Tunable Laser Market Analysis
Ekips Asthma Testing
Ekips Technologies
Given Diagnostic System

Oncology
Market Opportunities, Strategies, and Forecasts, 2006 to 2012

Between 2000 and 2020, the World Health Organization is predicting a 50% rise in the global incidence of cancer. Fortunately for those diagnosed with cancer between now and 2020, cancer treatments are also projected to evolve along with the cancer market, creating options for the afflicted.

However, these options come at a significant price. Prescription drug costs have spiraled from $12 billion annually in 1980 to $179 billion in 2003, according to the Center for Medicare and Medicaid Services. In addition, cancer drugs will be the fastest-growing part of the drug market for the next five years, with costs rising 20 percent a year, according to many analysts. Every major drug maker is now investing heavily in oncology, rushing to capitalize on new research about the way cancer cells reproduce.

With the cancer market struggling with few new drugs-only 1 of 20 cancer drugs developed reach the market-and expensive drugs, the FDA hopes to develop new tests to assess a patient's cancer. Instead of the old test that simply uses X-rays, the FDA wants to employ imaging, blood tests, as well as other techniques to better assess a patient's progression of cancer. X-rays only measure the size of the tumor, and a smaller tumor after use of a drug does not necessarily mean the tumor is any less dangerous. With these new tests to measure success against cancer, cancer drugs would be able to make it to market quicker.

Using chemotherapy as an example, patients with advanced disease used to live an average of one year, at a cost of $63 for an initial 8-week treatment. A newer drug regimen has extended survival to 21 months, but at a cost of $12,000. Situations like this stress the ailing U.S. health care system, raising questions about the cost of end-of-life care.

The oncology market will grow steadily due to numerous factors, including the aging population, new treatments available, the unraveling of the genetics behind cancer, and the fact that cancer is a significant disease with many variations.

The oncology market forecasts show an increase from 18 million in 2004 to over 195 Million in 2012.

Companies Profiled
Amgen
AstraZeneca
Genentech
Bristol-Myers Squibb
Millennium
OSI Pharmaceuticals
ImClone Systems
Sanofi-Aventis
Abgenix
Novartis
Eli Lilly
Merck
Onyx / Bayer
GlaxoSmithKline
Pfizer


Report Methodology

This is the 271st report in a series of market research reports that provide forecasts in communications, telecommunications, the internet, computer, software, and telephone equipment. The project leaders take direct responsibility for writing and preparing each report. They have significant experience preparing industry studies. Forecasts are based on primary research and proprietary data bases. Forecasts reflect analysis of the market trends in the segment and related segments. Unit and dollar shipments are analyzed through consideration of dollar volume of each market participation in the segment. Market share analysis includes conversations with key customers of products, industry segment leaders, marketing directors, distributors, leading market participants, and companies seeking to develop measurable market share. Over 200 in-depth interviews are conducted for each report with a broad range of key participants and opinion leaders in the market segment.

About the Company

WinterGreen Research, founded in 1985, provides strategic market assessments in telecommunications, communications equipment, health care, and advanced computer technology. Industry reports focus on opportunities that will expand existing markets or develop major new markets. The reports assess new product and service positioning strategies, new and evolving technologies, and technological impact on products, services, and markets. Market shares are provided. Leading market participants are profiled, and their marketing strategies, acquisitions, and strategic alliances are discussed. The principals of WinterGreen Research have been involved in analysis and forecasting of international business opportunities in telecommunications and advanced computer technology markets for over 30 years.

About the Principal Authors

Ellen T. Curtiss, Technical Director, co-founder of WinterGreen Research, conducts strategic and market assessments in technology-based industries. Previously she was a member of the staff of Arthur D. Little, Inc., for 23 years, most recently as Vice President of Arthur D. Little Decision Resources, specializing in strategic planning and market development services. She is a graduate of Boston University and the Program for Management Development at Harvard Graduate School of Business Administration. She is the author of recent studies on worldwide telecommunications markets and the Top Ten Telecommunications market analysis and forecasts.

Susan Eustis, President, co-founder of WinterGreen Research, has done research in communications and computer markets and applications. She holds several patents in microcomputing and parallel processing. She is the author of recent studies of the Regional Bell Operating Companies' marketing strategies, Internet equipment, a study of Internet Equipment, Worldwide Telecommunications Equipment, Top Ten Telecommunications, Digital Loop Carrier, Web Hosting, and Application Integration markets. Ms. Eustis is a graduate of Barnard College.

2006 WinterGreen Research, Inc. All Rights Reserved.